Abstract：【Objective】 To investigate the effect of bevacizumab combined with neoadjuvant chemotherapy on tumor marker levels and prognosis in patients with locally advanced cervical cancer.【Methods】 A total of 98 patients with locally advanced cervical cancer were randomly divided into the observation group and the control group, with 49 cases in each group. The control group was treated with a neoadjuvant chemotherapy regimen, while the observation group received bevacizumab in addition to the same chemotherapy regimen as control. Clinical efficacy, levels of T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), serum tumor markers [squamous cell carcinoma antigen (SCC), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA)], incidence of adverse reactions, and 1-year survival were compared between the two groups.【Results】 The objective response rate (ORR) and disease control rate (DCR) in the observation group were significantly higher than those in the control group (P<0.05). After treatment, the levels of CD4+ and CD4+/CD8+ increased, while CD8+ levels decreased in both groups (P<0.05); moreover, the observation group showed higher CD4+ and CD4+/CD8+ levels and lower CD8+ levels compared with the control group (P<0.05). After treatment, serum levels of CEA, CA125, and SCC in both control and observation groups were significantly lower than those before treatment (P<0.05), with the observation group showing significantly lower levels than the control group (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Both groups were followed up for 1 year postoperatively, and Kaplan-Meier survival analysis showed no statistically significant difference in survival rate between the two groups (Log-Rank=1.800, P=0.180).【Conclusion】 Bevacizumab combined with neoadjuvant chemotherapy can effectively improve clinical symptoms and reduce tumor marker levels in patients with locally advanced cervical cancer.
康红梅, 高冬梅, 王飞鹏, 姜晓春. 贝伐珠单抗联合新辅助化疗对局部晚期宫颈癌患者肿瘤标志物水平及预后的影响[J]. 医学临床研究, 2025, 42(5): 805-808.
KANG Hongmei, GAO Dongmei, WANG Feipeng, et al. Effect of Bevacizumab Combined with Neoadjuvant Chemotherapy on Tumor Marker Levels and Prognosis in Patients with Locally Advanced Cervical Cancer. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 805-808.
[1] WANG Z H, XIAO R R, HUANG J, et al. The diversity of vaginal microbiota predicts neoadjuvant chemotherapy responsiveness in locally advanced cervical cancer[J].Microb Ecol,2022,84(1):302-313. [2] 沈洁,莫淼,袁晶,等.1313例局部晚期宫颈癌患者的长期生存报告:以医院为基础的真实世界研究[J].中国癌症杂志,2020,30(3):192-198. [3] 李娜,李辉,马春雨,等.紫杉醇联合顺铂新辅助化疗与同步放化疗在局部晚期宫颈癌中的疗效评价[J].中国妇产科临床杂志,2019,20(3):227-229. [4] YAMAMOTO Y, YAMASHIRO H, TOH U, et al. Prospective observational study of bevacizumab combined with paclitaxel as first-or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study[J].Bresst Cancer,2021,28(1):145-160. [5] 王荣敏,彭晶晶,尤志学. 对ASCCP 2012年宫颈癌筛查和癌前病变管理指南的解读(二)[J].国际妇产科学杂志,2015,42(2):238-240. [6] 张余飞,康静波,温居一,等.RECIST 1.1标准和mRECIST标准在原发性肝癌SBRT治疗后疗效评价中的对比研究[J].中国肿瘤临床,2016,43(20):902-906. [7] 张贤雨,马欢,席强,等.局部晚期宫颈癌患者同步放化疗后应用TP方案巩固化疗效果及血清miR-155、miR-24水平变化[J].山东医药,2020,60(29):43-45. [8] 李美芳,赵萍萍,刘伟,等.贝伐珠单抗联合放疗及动脉栓塞灌注化疗药物治疗局部晚期宫颈癌的临床观察[J].医学影像学杂志,2022,32(7):1200-1203. [9] 赵昌芹,张瑞林. 局部晚期宫颈癌化疗及预后与化疗前免疫功能及血小板的相关性[J].热带医学杂志,2019,19(1):76-79. [10] 徐海波,姚涓,王君辉,等.不同腔内放疗治疗局部晚期宫颈癌近期疗效剂量学对比毒副反应及免疫功能的影响[J].河北医学,2021,27(12):2085-2090. [11] QIN S.Effect of bevacizumab combined with neoadjuvant chemotherapy in advanced ovarian cancer and the occurrence of adverse reactions[J].Anticancer Res,2021,5(6):52-56. [12] 宋春环,郑小莉,葛艳,等.肿瘤标志物检测在宫颈癌诊断中的应用探讨[J].中华肿瘤防治杂志,2018,25(2):89-90. [13] 宋晓婕,周艳艳,赵莉娜. 加味八珍汤联合放化疗对中晚期宫颈癌疗效及对患者T细胞亚群水平、血清肿瘤标志物表达及生存期的影响[J].中国实验方剂学杂志,2018,24(4):174-179. [14] 吴蕴春,华玉蓉,葛海艳.贝伐珠单抗联合长春瑞滨对宫颈癌患者血清因子表达水平的影响[J].医学研究生学报,2021,34(8):829-833.
2025, Vol. 42 
